Published in Hepatology on October 01, 2003
High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol (2007) 2.68
Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol (2009) 2.45
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J (2010) 2.43
Unbiased, genome-wide in vivo mapping of transcriptional regulatory elements reveals sex differences in chromatin structure associated with sex-specific liver gene expression. Mol Cell Biol (2010) 1.45
Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol (2006) 1.36
Sex differences in drug disposition. J Biomed Biotechnol (2011) 1.33
Liver-specific hepatocyte nuclear factor-4alpha deficiency: greater impact on gene expression in male than in female mouse liver. Mol Endocrinol (2008) 1.30
Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. Toxicol Sci (2011) 1.13
Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther (2008) 1.11
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med (2013) 1.11
Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation. Curr Pharmacogenomics Person Med (2009) 1.10
Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease. PLoS One (2011) 1.06
Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther (2009) 1.05
Sex-specific mouse liver gene expression: genome-wide analysis of developmental changes from pre-pubertal period to young adulthood. Biol Sex Differ (2012) 0.98
Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab (2010) 0.98
Gender-specific induction of cytochrome P450s in nonylphenol-treated FVB/NJ mice. Toxicol Appl Pharmacol (2006) 0.96
Muscular effects of statins in the elderly female: a review. Clin Interv Aging (2013) 0.96
Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos (2010) 0.95
Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol Hepatol (N Y) (2013) 0.94
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver. Front Pharmacol (2010) 0.93
Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR). Toxicology (2008) 0.92
Molecular mechanisms underlying chemical liver injury. Expert Rev Mol Med (2012) 0.91
Quantitation of human cytochrome P450 2D6 protein with immunoblot and mass spectrometry analysis. Drug Metab Dispos (2008) 0.91
Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol (2010) 0.90
Sex differences in the effectiveness of statins after myocardial infarction. CMAJ (2007) 0.90
A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos (2008) 0.90
Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther (2010) 0.90
Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J (2009) 0.90
Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system. Biomaterials (2012) 0.90
Toxicity Profile of the Aqueous Ethanol Root Extract of Corrigiola telephiifolia Pourr. (Caryophyllaceae) in Rodents. Evid Based Complement Alternat Med (2010) 0.89
Molecular Interactions between NAFLD and Xenobiotic Metabolism. Front Genet (2013) 0.88
Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms. Br J Pharmacol (2012) 0.86
Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. Br J Clin Pharmacol (2007) 0.85
Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men. Endocrinology (2011) 0.85
Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis. PLoS One (2013) 0.84
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. Br J Clin Pharmacol (2006) 0.83
Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma. Sarcoma (2013) 0.83
Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone. Drug Metab Dispos (2009) 0.83
Pharmacogenetics of anxiolytic drugs. J Neural Transm (Vienna) (2009) 0.83
A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes. BMC Syst Biol (2011) 0.82
Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis. Expert Opin Drug Metab Toxicol (2014) 0.81
Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS One (2010) 0.80
Inherent sex-dependent regulation of human hepatic CYP3A5. Br J Pharmacol (2013) 0.80
Perinatal exposure to perfluorooctane sulfonate affects glucose metabolism in adult offspring. PLoS One (2014) 0.79
Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort. Arq Bras Cardiol (2014) 0.78
Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.78
4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? Br J Clin Pharmacol (2015) 0.77
Sex Differences in HIV: Natural History, Pharmacokinetics, and Drug Toxicity. Curr Infect Dis Rep (2005) 0.77
Disruption of STAT5b-Regulated Sexual Dimorphism of the Liver Transcriptome by Diverse Factors Is a Common Event. PLoS One (2016) 0.77
Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice. Eur J Clin Pharmacol (2008) 0.77
Gene copy number variation analysis reveals dosage-insensitive expression of CYP2E1. Pharmacogenomics J (2015) 0.76
miRNA-27b levels are associated with CYP3A activity in vitro and in vivo. Pharmacol Res Perspect (2015) 0.76
Gender differences in pharmacokinetics and pharmacodynamics of methadone substitution therapy. Front Pharmacol (2015) 0.76
In vitro analysis of factors influencing CYP1A2 expression as potential determinants of interindividual variation. Pharmacol Res Perspect (2017) 0.75
Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. Front Pharmacol (2016) 0.75
Gender-specific differences in hypothalamus-pituitary-adrenal axis activity during childhood: a systematic review and meta-analysis. Biol Sex Differ (2017) 0.75
Peroxisome proliferator-activated receptor alpha, PPARα, directly regulates transcription of cytochrome P450 CYP2C8. Front Pharmacol (2015) 0.75
A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms. Stem Cell Rev (2017) 0.75
Role of TRPA1 in acute cardiopulmonary toxicity of inhaled acrolein. Toxicol Appl Pharmacol (2016) 0.75
Population pharmacokinetics of omeprazole in a random Iranian population. Caspian J Intern Med (2013) 0.75
Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort. Br J Clin Pharmacol (2006) 0.75
17β-Estradiol up-regulates UDP-glucuronosyltransferase 1A9 expression via estrogen receptor α. Acta Pharm Sin B (2016) 0.75
Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs. Biosci Rep (2017) 0.75
Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. Eur J Clin Pharmacol (2016) 0.75
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 14.54
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther (2013) 3.81
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol (2012) 3.61
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol (2004) 3.56
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol (2008) 3.53
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA (2013) 3.46
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol (2003) 3.34
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology (2003) 2.97
Using trade names: a risk factor for accidental drug overdose. Arch Intern Med (2002) 2.91
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics (2002) 2.68
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther (2004) 2.68
Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology (2009) 2.59
Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension (2004) 2.32
Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics (2004) 2.32
Senescence rates are determined by ranking on the fast-slow life-history continuum. Ecol Lett (2008) 2.30
Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs (2007) 2.26
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem (2008) 2.24
Biliary reconstruction using a side-to-side choledochocholedochostomy with or without T-tube in deceased donor liver transplantation: a prospective randomized trial. Ann Surg (2009) 2.19
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol (2012) 2.15
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. Am J Transplant (2005) 2.08
Different cava reconstruction techniques in liver transplantation: piggyback versus cava resection. Hepatobiliary Pancreat Dis Int (2014) 2.08
The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C. Hepatology (2011) 2.08
Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg (2009) 2.06
Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics (2005) 1.95
Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl (2011) 1.92
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis (2010) 1.91
Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial. Ann Surg (2007) 1.90
The surgical treatment of bilateral benign nodular goiter: balancing invasiveness with complications. Dtsch Arztebl Int (2014) 1.88
Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ (2002) 1.88
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 1.87
Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther (2004) 1.86
When good drugs go bad. Nature (2007) 1.85
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics (2007) 1.84
Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem (2008) 1.84
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics (2007) 1.84
Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation. Transpl Int (2009) 1.77
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther (2005) 1.74
Hepatic artery thrombosis after adult liver transplantation. Liver Transpl (2003) 1.74
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA (2005) 1.74
The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol (2007) 1.73
Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol (2011) 1.69
Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med (2015) 1.68
Trends and experiences in liver retransplantation over 15 years. Liver Transpl (2007) 1.66
Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet (2007) 1.66
Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem (2010) 1.66
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics (2003) 1.63
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther (2008) 1.62
Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology (2003) 1.59